{"id":62464,"date":"2026-01-09T01:06:01","date_gmt":"2026-01-09T00:06:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/"},"modified":"2026-01-09T01:06:01","modified_gmt":"2026-01-09T00:06:01","slug":"fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/","title":{"rendered":"FineHeart Secures \u20ac83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs)"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>\u20ac35 million Series C funding to accelerate the clinical and industrial development of FlowMaker<sup>\u00ae<\/sup><\/b><\/li>\n<li>\n<b>\u20ac48 million in grants from the IPCEI <i>Tech4Cure<\/i> program to structure the European Active Implantable Medical Devices (AIMD) sector<\/b><\/li>\n<\/ul>\n<p>BORDEAUX, France&#8211;(BUSINESS WIRE)&#8211;FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announced today the completion of a \u20ac35 million first closing of its Series C financing round. This funding is a key lever for activating European public funding, IPCEI <i>Tech4Cure<sup>1<\/sup><\/i>, and for establishing its role as a European Active Implantable Medical Devices (AIMDs) leader.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260108869161\/en\/2687039\/5\/Logo_FineHeart_D%C3%A9f.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260108869161\/en\/2687039\/22\/Logo_FineHeart_D%C3%A9f.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260108869161\/en\/2687039\/5\/Logo_FineHeart_D%C3%A9f.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260108869161\/en\/2687039\/21\/Logo_FineHeart_D%C3%A9f.jpg\"><\/a><\/p>\n<p>\nIn total, FineHeart has secured \u20ac83 million in financing combining private capital and non-dilutive European public funding to accelerate the industrialization and clinical development of FlowMaker<sup>\u00ae<\/sup> and establish itself as a future European AIMD leader.<\/p>\n<p>\n<b>Arnaud Mascarell, CEO and co-founder of FineHeart<\/b>, said: <b><i>\u201cWe are delighted to welcome new investors at this first closing. I would like to extend my special thanks to Groupe Pasteur Mutualit\u00e9 and the European Innovation Council (EIC) for their key contributions, as well as to our long-standing shareholders, led by FH Founders, for their unwavering support. T<\/i><i>ogether with the IPCEI, this funding strengthens our ambition to build disruptive, IP-protected technologies that enable more predictive, personalized, preventive, and participatory medicine\u2014while advancing Europe\u2019s industrial competitiveness and healthcare sovereignty.<\/i><i>\u201d<\/i><\/b><\/p>\n<p>\n<b>A first \u20ac35 million closing, paving the way for the remainder of the Series C round.<\/b><\/p>\n<p>\nThis first \u20ac35 million closing brings together new investors, including Groupe Pasteur Mutualit\u00e9 and Groupe Etchart, alongside significant participation from the European Innovation Council (EIC)\u2019s EIB fund. Existing investors\u2014FH Founders (the founders\u2019 holding company bringing together primarily international private investors from healthcare and entrepreneurship), Lurra, IRDI, Groupe Doliam and NACO\u2014renew their confidence and support this next FlowMaker development phase.<\/p>\n<p>\n\u201cGroupe Pasteur Mutualit\u00e9 acts for health by combining prevention, solidarity, and support for innovation. By supporting FineHeart, we fund a technology that can transform the treatment of severe heart failure, driven by the same ambition: to advance health for everyone,\u201d declared Thierry Lorente, Managing Director of Groupe Pasteur Mutualit\u00e9.<\/p>\n<p>\n<b>\u20ac48 million in grants under the IPCEI <i>Tech4Cure<sup>1<\/sup>:<\/i> FineHeart, European leader in AIMDs<\/b><\/p>\n<p>\nIn parallel, FineHeart is to benefit from \u20ac48 million in grants from the IPCEI <i>Tech4Cure<\/i> program, disbursed in several tranches, in its role as the lead partner in the project to structure the European AIMD sector. The work will focus on key technological challenges inherent to AIMDs, including:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nMiniaturization of power supply systems,<\/li>\n<li>\nDrastic reduction of energy requirements,<\/li>\n<li>\nLong-term reliability and durability of implantable systems.<\/li>\n<\/ul>\n<p>\nThese innovations form a technological pillar of FlowMaker<sup>\u00ae<\/sup> developed by FineHeart<\/p>\n<p>\nThe advisors involved in this transaction:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nLegal advisors : Olivier Mourain &amp; cabinet La Tour International &#8211; <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Flatourinternational.com%2Fen%2F&amp;esheet=54392528&amp;newsitemid=20260108869161&amp;lan=en-US&amp;anchor=La+Tour+International&amp;index=1&amp;md5=b9258eec5447d2fa6b202c59b7a0b1ef\" rel=\"nofollow\" shape=\"rect\">La Tour International<\/a><\/li>\n<li>\nAuditors : Aeccelis &amp; Forvis Mazars <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.forvismazars.com%2Ffr%2Ffr%2Fsecteurs&amp;esheet=54392528&amp;newsitemid=20260108869161&amp;lan=en-US&amp;anchor=Secteurs+-+Forvis+Mazars&amp;index=2&amp;md5=3d0ffa64bf726d0b8b5b1a5700812cd4\" rel=\"nofollow\" shape=\"rect\">Secteurs &#8211; Forvis Mazars<\/a><\/li>\n<li>\nHelinnov conseil<\/li>\n<\/ul>\n<p>\n<b>About FlowMaker<sup>\u00ae<\/sup><\/b><\/p>\n<p>\n<b>FlowMaker<sup>\u00ae<\/sup><\/b> is the world\u2019s first fully implantable cardiac output accelerator designed to treat advanced heart failure. Fully intraventricular, it provides physiological support synchronized with the natural heart contractions. It respects natural blood flow and does not require aortic bypass. By operating in synergy with native cardiac contractions, the FlowMaker<sup>\u00ae<\/sup> consumes little energy and does not require any percutaneous connection to external batteries. It is recharged via a transcutaneous energy transfer (TET) system, thereby reducing any risk of infection and significantly improving patients&#8217; quality of life. The device is implanted through a minimally invasive procedure on a beating heart, with an average duration of 90 minutes. This procedure is widely practiced by cardiac surgeons and limits any physiological changes.<\/p>\n<p>\n<b>About FineHeart \u2013 <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fineheart.com&amp;esheet=54392528&amp;newsitemid=20260108869161&amp;lan=en-US&amp;anchor=www.fineheart.com&amp;index=3&amp;md5=ec7a8fcc5964beb9ebdfddd8d5122a67\" rel=\"nofollow\" shape=\"rect\">www.fineheart.com<\/a><\/b><\/p>\n<p>\n<b>FineHeart <\/b>is a clinical-stage medical device company based in Bordeaux and Tours. Its innovative product, FlowMaker<sup>\u00ae<\/sup>, could treat 200,000 patients with advanced heart failure every year. FineHeart is initially targeting the 50,000 most severe patients eligible for cardiac assistance and not treated by current LVADs. This first potential market is estimated at over 5 billion euros.<\/p>\n<p>\nFineHeart was founded by CEO Arnaud Mascarell and a team of internationally renowned cardiac surgeons and electro-physiologists, including Dr. St\u00e9phane Garrigue, CSO and inventor of the concept, and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy (CRT). The company holds an international portfolio of 160 patents in 27 different families.<\/p>\n<p>\nFinanced by a consortium of public and private investors, including the founders&#8217; holding company, FH Founders, as well as Doliam, Etchart Group, and investment funds Groupe Pasteur Mutualit\u00e9, Lurra, Aquiti Gestion, Galia Gestion, Broadview Ventures, IRDI Capital Investment, M Capital, UI Investment &amp; Verve Capital. FineHeart is supported by the European Union (EIC), Bpifrance and the Nouvelle-Aquitaine and Centre-Val de Loire regions.<\/p>\n<p>\n<sup>1<\/sup>Important Project of Common European Interest (&#8216;IPCEI&#8217;) Tech4Cure.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Europe<\/b><br \/>Media Relations<br \/>\n<br \/>Annie-Florence Loyer<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#x6f;:&#x61;&#102;&#x6c;&#x6f;y&#x65;&#114;&#x40;&#x6e;e&#x77;&#99;&#x61;&#x70;&#46;&#x66;&#114;\" rel=\"nofollow\" shape=\"rect\">af&#108;&#111;&#121;&#101;&#x72;&#x40;&#x6e;&#x65;&#x77;ca&#112;&#46;&#102;&#114;<\/a><br \/>+33 (6) 88 20 35<\/p>\n<p>\n<b>FineHeart Communications<\/b><br \/>James Palmer<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;:&#106;&#x2e;&#x70;a&#108;&#x6d;e&#114;&#x40;&#x6f;r&#112;&#x68;e&#111;&#x6e;&#x66;&#105;&#110;&#x61;n&#99;&#x65;&#x2e;&#99;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">j&#46;pa&#108;&#109;&#101;&#114;&#64;&#x6f;&#x72;&#x70;&#x68;&#x65;&#x6f;&#x6e;fina&#110;&#99;&#101;&#46;&#99;&#x6f;&#x6d;<\/a><br \/>+33 (0) 7 60 92 77 72<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u20ac35 million Series C funding to accelerate the clinical and industrial development of FlowMaker\u00ae \u20ac48 million in grants from the IPCEI Tech4Cure program to structure the European Active Implantable Medical Devices (AIMD) sector BORDEAUX, France&#8211;(BUSINESS WIRE)&#8211;FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announced today the completion of &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62464","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FineHeart Secures \u20ac83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FineHeart Secures \u20ac83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u20ac35 million Series C funding to accelerate the clinical and industrial development of FlowMaker\u00ae \u20ac48 million in grants from the IPCEI Tech4Cure program to structure the European Active Implantable Medical Devices (AIMD) sector BORDEAUX, France&#8211;(BUSINESS WIRE)&#8211;FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announced today the completion of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-09T00:06:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260108869161\/en\/2687039\/22\/Logo_FineHeart_D%C3%A9f.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"FineHeart Secures \u20ac83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs)\",\"datePublished\":\"2026-01-09T00:06:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\\\/\"},\"wordCount\":797,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260108869161\\\/en\\\/2687039\\\/22\\\/Logo_FineHeart_D%C3%A9f.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\\\/\",\"name\":\"FineHeart Secures \u20ac83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260108869161\\\/en\\\/2687039\\\/22\\\/Logo_FineHeart_D%C3%A9f.jpg\",\"datePublished\":\"2026-01-09T00:06:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260108869161\\\/en\\\/2687039\\\/22\\\/Logo_FineHeart_D%C3%A9f.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260108869161\\\/en\\\/2687039\\\/22\\\/Logo_FineHeart_D%C3%A9f.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FineHeart Secures \u20ac83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FineHeart Secures \u20ac83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/","og_locale":"en_US","og_type":"article","og_title":"FineHeart Secures \u20ac83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs) - Pharma Trend","og_description":"\u20ac35 million Series C funding to accelerate the clinical and industrial development of FlowMaker\u00ae \u20ac48 million in grants from the IPCEI Tech4Cure program to structure the European Active Implantable Medical Devices (AIMD) sector BORDEAUX, France&#8211;(BUSINESS WIRE)&#8211;FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announced today the completion of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-09T00:06:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260108869161\/en\/2687039\/22\/Logo_FineHeart_D%C3%A9f.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"FineHeart Secures \u20ac83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs)","datePublished":"2026-01-09T00:06:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/"},"wordCount":797,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260108869161\/en\/2687039\/22\/Logo_FineHeart_D%C3%A9f.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/","url":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/","name":"FineHeart Secures \u20ac83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260108869161\/en\/2687039\/22\/Logo_FineHeart_D%C3%A9f.jpg","datePublished":"2026-01-09T00:06:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260108869161\/en\/2687039\/22\/Logo_FineHeart_D%C3%A9f.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260108869161\/en\/2687039\/22\/Logo_FineHeart_D%C3%A9f.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/fineheart-secures-e83-million-to-support-its-growth-and-establish-itself-as-a-future-european-leader-in-active-implantable-medical-devices-aimds\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"FineHeart Secures \u20ac83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62464"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62464\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}